Evidence map›Paper›PMID 32660185›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2020

[Research progress on the clinical features and mechanisms of COVID-19 combined with liver injury].

Y B Xie, S Y Wang, C Zhang, F S Wang

Abstract read
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Y B XieMedical School of Chinese PLA, Beijing 100853, China; Treatment and Research Center of Infectious Diseases,The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
S Y WangMedical School of Chinese PLA, Beijing 100853, China; Treatment and Research Center of Infectious Diseases,The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
C ZhangTreatment and Research Center of Infectious Diseases,The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
F S WangTreatment and Research Center of Infectious Diseases,The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The highly contagious novel coronavirus pneumonia (COVID-19) that broke out in December 2019 has brought huge threats and losses to human society, so it has been the concern of every countries government. Presently, there are no specific drugs for COVID-19; however, a variety of potentially effective antiviral drugs, vaccines, cell therapies, traditional Chinese medicine and other methods are in clinical trials. Liver injury is a common complication of patients receiving COVID-19 treatment and its possible high incidence may affect the outcome of the disease. The pathogenesis of COVID-19 combined with liver injury in existing studies is still unclear, and relevant guidelines and expert consensuses are insufficient for clinical diagnosis and treatment. Therefore, the relevant progress and issues are now reviewed here.

Indexed as

BetacoronavirusCoronavirus InfectionsPandemicsPneumonia, ViralCOVID-19COVID-19 Drug TreatmentHumansLiverLiver DiseasesSARS-CoV-2COVID-19Liver injurySARS-CoV-2 (Severe Acute Respiratory Syndrome Voronavirus 2)

Identifiers

PMID32660185
PMCPMC12769515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.